They are changing their chief executives, shifting their strategies, acquiring new companies and pumping money into ever more alliances for drug research. Yet, in spite of intense recent change by the pharmaceutical companies, the markets still eye them with suspicion.
A decade ago, the leading international drug manufacturers were viewed as solidly performing growth stocks, precisely the “safe harbours” to which investors would turn at a time of low confidence such as the period now affecting equity markets.
